Published in final edited form as:

J Am Chem Soc. 2016 July 13; 138(27): 8376–8379. doi:10.1021/jacs.6b04330.

Synthesis of a Potent Vinblastine: Rationally Designed Added Benign Complexity

Oliver Allemann, Manuela Brutsch, John C. Lukesh III, Daniel M. Brody, and Dale L. Boger*

Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

Abstract

Many natural products, including vinblastine, have not been easily subjected to simplifications in their structures by synthetic means or modifications by late-stage semi-synthetic derivatization in ways that enhance their biological potency. Herein, we detail a synthetic vinblastine that incorporates added benign complexity (ABC), which improves activity 10-fold, and is now accessible as a result of advances in the total synthesis of the natural product. The compound incorporates designed added molecular complexity but no new functional groups, and maintains all existing structural and conformational features of the natural product. It constitutes a member of an analogue class presently inaccessible by semi-synthetic derivatization of the natural product, by its late-stage functionalization, or by biosynthetic means. Rather, it was accessed by synthetic means, using an appropriately modified powerful penultimate single-step vindoline-catharanthine coupling strategy that proceeds with a higher diastereoselectivity than found for the natural product itself.

TOC image

*Corresponding Author: boger@scripps.edu(D.L.B.).

Supporting Information

Full experimental details and copies of ^1H NMR spectra are provided. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Notes: The authors declare no competing financial interests.

Vinblastine (**1**) and vincristine (**2**) were originally isolated from *Catharanthus roseus* (L.) G. Don^{1,2} and are the most widely recognized members of the *Vinca* alkaloids (Figure 1). They have a rich history and were among the first natural products introduced clinically to treat cancer.³ Their discovery defined an important antineoplastic mechanism of action, entailing the inhibition of mitosis via tubulin binding and inhibition of microtubule polymerization,⁴ that today is regarded as one of the most successful drug targets in oncology. Although additional natural products have been shown subsequently to act on tubulin (e.g., taxol, epothilones, eleutherobin, dolastatins), vinblastine and vincristine differ in that they bind at the tubulin–tubulin head-to-tail dimer interface.⁵ Because of their clinical importance, complex structures, and unique mechanism of action, vinblastine and vincristine have attracted extensive synthetic and mechanistic efforts since their original discovery.^{3,6,7}

In recent studies, we described concise total syntheses of vinblastine and related natural products based in part on introduction of a powerful single-pot two-step diastereoselective Fe(III)-promoted vindoline/catharanthine coupling and subsequent Fe(III)-NaBH₄/air mediated in situ C20' oxidation.^{8,9} These developments have permitted systematic studies of the effects of deep-seated changes in the natural product structures within either the lower vindoline or upper catharanthine-derived velbanamine subunits.⁹ Among the most significant of the observations made to date in these studies is that while removal of individual substituents or key structural components of the natural products typically results in reductions in biological activity,^{8–14} addition of structural features can substantially improve biological properties.^{15,16} As a result of our demonstration of the importance of the addition of a key indole C10' substituent (10'-fluorovinblasine)¹⁵ and with the discovery of the remarkable impact of select C20' alcohol replacements (C20' ureas),¹⁶ it appeared that the spatial placement of the indole at one end of velbanamine and the C20' ethyl group at the other are two especially important features of the structure. The X-ray structure of tubulin-bound vinblastine⁵ (Figure 2) indicates both fit into well-defined protein pockets on the tubulin α and β subunits, respectively, deeply embedded in the tubulin binding site with each

occupying corners of a T-shaped bound conformation of vinblastine. The core of the velbanamine subunit fills the intervening space and serves as a rigid scaffold that fixes the placement of these two anchoring groups.

Herein, we report a compound, representative of a strategy rarely considered with complex natural products, where increasing the complexity of the core structure provided a stunning 10-fold enhancement in the biological potency. The results are sufficiently remarkable to suggest that even in instances where Nature appears to have optimized a natural product structure for activity, addition of even seemingly benign complexity to its underlying core structure may be possible that further and substantially improves on what Nature only started. For vinblastine and the work herein, this entailed incorporation of the C20' ethyl group into an added C15'–C20' cis-fused 6-membered ring, that further fills the C20' ethyl binding pocket. Unlike molecular editing of structures by diverted synthesis,¹⁷ the addition of a key functional group, derivatization of the natural product, tactics of simplification of complex biologically active natural products,¹⁸ or introduction of conformational constraints,¹⁹ the design of **7** entails introduction of added benign complexity (ABC) to the underlying core structure of vinblastine (two added sp³ methylenes and a stereocenter) to more favorably occupy and fill a protein binding site without changing the intrinsic conformational or structural features of the natural product. Compound **7** represents a member of an analogue class inaccessible by semi-synthetic derivatization of the natural product, by its late-stage functionalization, or by biosynthetic means, but was prepared herein by late-stage divergent synthesis²⁰ based on the penultimate single-step vindoline-catharanthine coupling strategy. Its synthesis used **6**, bearing an alkene exocyclic (vs endocyclic) to the catharanthine skeleton, that incorporates the added fused six-membered ring and additional C15' stereochemistry (Figure 2). This change in the substrate also substantially improved the diastereoselectivity (>6:1 vs 2:1) of the in situ alkene oxidation reaction used for introduction of the C20' alcohol while maintaining the exclusive generation of the natural C16' stereochemistry at the critical coupling site.

Following a known 3-step synthesis,²¹ intermediate **11** was prepared from the free base of catharanthine (**4**, \$16/g) by indole protection (2.5 equiv KH, THF, 0 °C; 2.5 equiv ClCO₂Me, 0–23 °C, 15 h, 90%), single-step conversion of **9** to the lactam **10** (4.5 equiv I₂, 9 equiv Na₂CO₃, THF/H₂O, 0–23 °C, 22 h, 82%) and subsequent allylic oxidation (2 equiv SeO₂, THF, 65 °C, 18 h, 60%) under modified reaction conditions (THF vs EtOH) that substantially reduced the amount of required SeO₂ (2 vs 11 equiv) (Scheme 1). Starting with **11**, acid-catalyzed elimination of the secondary allylic alcohol (0.6 equiv TsOH, toluene, 110 °C, Dean–Stark trap, 2.5 h, 97%) cleanly provided the diene **12** poised for introduction of the fused unsaturated six-membered ring by a Diels–Alder reaction. Treatment of **12** with phenyl vinylsulfone (2 equiv, toluene, 110 °C, 45 h, 61%) provided **13** as an inconsequential mixture of cycloadduct isomers derived from β-face (top face) addition of the dienophile with installation of the C15' stereochemistry. Mild reductive removal of the phenyl sulfone with Mg (10 equiv, MeOH, 23 °C, 4 h) and deliberate completion of the in situ methanolysis of the indole carbamate (6.5 equiv K₂CO₃, MeOH, 23 °C, 1 h) provided **14** (65% for 2 steps), whose structure and stereochemistry were confirmed in a single-crystal X-ray structure determination.²² Final reduction of the lactam **14** (5 equiv 9-BBN, THF, 23 °C, 8

h, 59%) afforded the key substrate **6** (5 steps from known intermediate **11**, 8 steps from catharanthine) for coupling with vindoline.

Single-step incorporation of **6** into the targeted vinblastine **7** by room temperature Fe(III)-promoted single electron oxidative coupling with vindoline (**3**, \$36/g) in aqueous 0.05 N HCl/trifluoroethanol (TFE, 10:1, 5 equiv FeCl₃, 23 °C, 3 h) followed by in situ Fe(III)-promoted free radical oxidation of the trisubstituted alkene found in **8** (Fe₂(ox)₃, NaBH₄, air, 0 °C, 30 min) proceeded with complete control of the C16' stereochemistry and good diastereoselectivity for C20' alcohol introduction (>6:1) (Figure 3). The latter represents an increased diastereoselectivity for the C20' alcohol introduction relative to that observed with vinblastine itself (2:1)⁸ and may be attributed to the added α -face C15' steric hindrance for reaction of O₂ with the intermediate tertiary radical derived from Fe(III)/NaBH₄-mediated hydrogen atom addition to intermediate **8**. Significantly, the fused six-membered ring in **6** did not impact the exclusive α -face Fe(III)-promoted coupling with vindoline.^{8,23} This reaction is thought to proceed by single electron oxidation of **6** to the indole-centered radical cation and its reversible fragmentation to an intermediate charge-separated cation radical that undergoes radical addition to vindoline.⁸ It is of special note that this initial coupling still occurs with exclusive control of the C16' stereochemistry, with clean stereochemical inversion at the reacting C16' center, despite the increased steric hindrance due to the added C15' substitution. This observation is supportive of the suggested intermediacy of an intramolecular one-electron-two-center bonding interaction between the putative C16' radical site and the fragmented iminium carbon that may stabilize a conformation dictating backside addition of vindoline.^{8c}

Compound **7** was assessed alongside vinblastine as a direct comparison in cell growth inhibition assays against both a mouse leukemia (L1210) and human colon cancer (HCT116) cell line that have been used traditionally to initially examine vinblastine analogues (Figure 3).²⁴ Consistent with the design but stunning nonetheless, compound **7** proved to be 10-fold more potent than vinblastine, displaying an IC₅₀ of 600–700 pM in the cell growth inhibition assays.

To confirm that the improved activity of **7** is derived from tubulin binding effects, compound **7** was compared alongside vinblastine in a tubulin binding assay, measuring their relative ability to competitively displace BODIPY-vinblastine (Figure 4).²⁵ Compound **7** was found to displace BODIPY-vinblastine bound to tubulin much more effectively than vinblastine itself, confirming that it binds the same site and with a much higher affinity. Although it is not possible to rule out the impact of other features,²⁶ this direct correlation of functional cell growth inhibition activity with target tubulin binding affinity, the relative magnitude of the effects, and the small benign structural differences between **1** and **7** suggest that the improved potency of **7** is derived predominately, if not exclusively, from on target effects on tubulin. The modeled binding of **7** with tubulin is presented in Supporting Information Figure S1.

Approaches to improving the properties of natural products typically involve efforts to simplify or edit their structures through semi-synthetic modifications, diverted total synthesis, or late-stage (C–H) functionalization. Such efforts often strive to remove,

introduce, identify or replace key functional groups to enhance target binding affinity, improve physiochemical properties, incorporate stabilizing modifications, or introduce conformational constraints. Rarely, if ever, does one consider adding benign molecular complexity to the underlying core structure.²⁷ In part, this may be attributed to the perceived added challenge intrinsic in the requisite compound synthesis. Herein, we describe the synthesis of a rationally designed ABC (added benign complexity)²⁷ modification to vinblastine that was as accessible as the natural product or its simplified analogues, that enhanced the stereochemical control of the underlying synthesis, and that provided an analogue 10-fold more potent than the natural product. The compound represents a vinblastine analogue accessible only by chemical synthesis and is presently inaccessible by natural product derivatization, late-stage functionalization, or biosynthetic methods. Moreover, in instances when the productive properties of a natural product are directly related to its emergence in Nature and has undergone continued optimization by natural selection as is likely the case with vinblastine, it may not be easily subjected to structural simplifications. In such cases, it is possible that added molecular complexity^{15,16} may be used to enhance target binding and functional biological activity, and approaches as simple as ABC illustrated herein may represent a rational conceptual approach to achieving such objectives.²⁸

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the financial support of the National Institutes of Health (CA042056 and CA115526, D.L.B.), the Skaggs Institute for Chemical Biology and the Swiss National Science Foundation for fellowship support (O.A.; PZZHP2_158958). We especially wish to thank Professor A. L. Rheingold and Dr. Curtis E. Moore (UCSD) for the single crystal X-ray structure determination of **14**.

References

1. (a) Noble RL, Beer CT, Cutts JH. Ann NY Acad Sci. 1958; 76:882. [PubMed: 13627916] (b) Noble RL. Lloydia. 1964; 27:280. Review: (c) Nobel RL. Biochem Cell Biol. 1990; 68:1344. [PubMed: 2085431]
2. Svoboda GH, Neuss N, Gorman M. J Am Pharm Assoc, Sci Ed. 1959; 48:659.
3. For a comprehensive review of the chemistry, medicinal chemistry, biology, and clinical applications, see: (a) Kuehne, ME.; Marko, I. Syntheses of vinblastine-type alkaloids. In: Brossi, A.; Suffness, M., editors. The Alkaloids. Vol. 37. Academic; San Diego: 1990. p. 77-131. (b) Borman, LS.; Kuehne, ME. Functional hot spot at the C-20? position of vinblastine. In: Brossi, A.; Suffness, M., editors. The Alkaloids. Vol. 37. Academic; San Diego: 1990. p. 133-144. (c) Pearce, HL. Medicinal chemistry of bisindole alkaloids. In: Brossi, A.; Suffness, M., editors. The Alkaloids. Vol. 37. Academic; San Diego: 1990. p. 145-204. (d) Neuss, N.; Neuss, MN. Therapeutic use of bisindole alkaloids from *Catharanthus*. In: Brossi, A.; Suffness, M., editors. The Alkaloids. Vol. 37. Academic; San Diego: 1990. p. 229-240.
4. Reviews: (a) Timasheff S, Andreu J, Gorbunoff M, Medranot F, Prakash V. Cellular Pharmacol. 1993; 1:S27. (b) Jordan MA, Wilson L. Nature Rev Cancer. 2004; 4:253. [PubMed: 15057285]
5. Gigant B, Wang C, Ravelli RBG, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M. Nature. 2005; 435:519. [PubMed: 15917812]
6. (a) Langlois N, Gueritte F, Langlois Y, Potier P. J Am Chem Soc. 1976; 98:7017. [PubMed: 965661] Mangeney P, Andriamialisoa RZ, Langlois N, Langlois Y, Potier P. J Am Chem Soc. 1979;

- 101:2243.(b) Kutney JP, Hibino T, Jahngen E, Okutani T, Ratcliffe AH, Treasurywala AM, Wunderly S. *Helv Chim Acta*. 1976; 59:2858. [PubMed: 1017976] Kutney JP, Choi LSL, Nakano J, Tsukamoto H, McHugh M, Boulet CA. *Heterocycles*. 1988; 27:1845.(c) Kuehne ME, Matson PA, Bornmann WG. *J Org Chem*. 1991; 56:513. Bornmann WG, Kuehne ME. *J Org Chem*. 1992; 57:1752. Kuehne ME, Zebovitz TC, Bornmann WG, Marko I. *J Org Chem*. 1987; 52:4340.(d) Magnus P, Stamford A, Ladlow M. *J Am Chem Soc*. 1990; 112:8210. Magnus P, Mendoza JS, Stamford A, Ladlow M, Willis P. *J Am Chem Soc*. 1992; 114:10232.(e) Yokoshima S, Ueda T, Kobayashi S, Sato A, Kuboyama T, Tokuyama H, Fukuyama T. *J Am Chem Soc*. 2002; 124:2137. [PubMed: 11878966]
7. Reviews:(a) Potier P. *J Nat Prod*. 1980; 43:72.(b) Kutney JP. *Nat Prod Rep*. 1990; 7:85.
8. (a) Ishikawa H, Colby DA, Boger DL. *J Am Chem Soc*. 2008; 130:420. [PubMed: 18081297] (b) Ishikawa H, Colby DA, Seto S, Va P, Tam A, Kakei H, Rayl TJ, Hwang I, Boger DL. *J Am Chem Soc*. 2009; 131:4904. [PubMed: 19292450] (c) Gotoh H, Sears JE, Eschenmoser A, Boger DL. *J Am Chem Soc*. 2012; 134:13240. [PubMed: 22856867] (d) Leggans EK, Barker TJ, Duncan KK, Boger DL. *Org Lett*. 2012; 14:1428. [PubMed: 22369097]
9. Sears JE, Boger DL. *Acc Chem Res*. 2015; 48:653. [PubMed: 25586069]
10. Sasaki Y, Kato D, Boger DL. *J Am Chem Soc*. 2010; 132:13533. [PubMed: 20809620]
11. Tam A, Gotoh H, Robertson WM, Boger DL. *Bioorg Med Chem Lett*. 2010; 20:6408. [PubMed: 20932748]
12. Va P, Campbell EL, Robertson WM, Boger DL. *J Am Chem Soc*. 2010; 132:8489. [PubMed: 20518465]
13. Schleicher KD, Sasaki Y, Tam A, Kato D, Duncan KK, Boger DL. *J Med Chem*. 2013; 56:483. [PubMed: 23252481]
14. Sears JE, Barker TJ, Boger DL. *Org Lett*. 2015; 17:5460. [PubMed: 26457536]
15. Gotoh H, Duncan KK, Robertson WM, Boger DL. *ACS Med Chem Lett*. 2011; 2:948. [PubMed: 22247789]
16. (a) Leggans EK, Duncan KK, Barker TJ, Schleicher KD, Boger DL. *J Med Chem*. 2013; 56:628. [PubMed: 23244701] (b) Barker TJ, Duncan KK, Otrubova K, Boger DL. *ACS Med Chem Lett*. 2013; 4:985.
17. Wilson RM, Danishefsky SJ. *J Org Chem*. 2006; 71:8329. [PubMed: 17064003]
18. Reviews:(a) Szpilman AM, Carreira EM. *Angew Chem Int Ed*. 2010; 49:9592.(b) Hong J. *Chem Eur J*. 2014; 20:10204. [PubMed: 25043880]
19. (a) Martin SF, Clements JH. *Ann Rev Biochemistry*. 2013; 82:267.(b) Larsen EM, Wilson MR, Taylor RE. *Nat Prod Rep*. 2015; 32:1183. [PubMed: 25974024]
20. (a) Boger DL, Brotherton CE. *J Org Chem*. 1984; 49:4050.(b) Mullican MD, Boger DL. *J Org Chem*. 1984; 49:4033.(c) Mullican MD, Boger DL. *J Org Chem*. 1984; 49:4045.
21. Giovannelli E, Leroux S, Moisan L, Carreyre H, Thuery P, Buisson D-A, Meddour A, Coustard J-M, Thibaudeau S, Rousseau B, Nicolas M, Hellier P, Doris E. *Org Lett*. 2011; 13:4116. [PubMed: 21732596]
22. The structure of 14 was confirmed in a single-crystal X-ray structure determination conducted on colorless rods grown from CH₂Cl₂ and has been deposited with the Cambridge Crystallographic Data Center (CCDC 1475224).
23. (a) Vukovic J, Goodbody AE, Kutney JP, Misawa M. *Tetrahedron*. 1988; 44:325.(b) Szantay C Jr, Balazs J, Bolcskei J, Szantay C. *Tetrahedron*. 1991; 47:1265.(c) Sundberg RJ, Hong J, Smith SQ, Sabato M, Tabakovic I. *Tetrahedron*. 1998; 54:6259.
24. Kuehne ME, Bornmann WG, Marko I, Qin Y, Le Boulluec KL, Frasier DA, Xu F, Malamba T, Ensinger CL, Borman LS, Huot AE, Exon C, Bizzarro FT, Cheung JB, Bane SL. *Org Biomol Chem*. 2003; 1:2120. [PubMed: 12945903]
25. (a) Jiang JD, Davis AS, Middleton K, Ling YH, Perez-Soler R, Holland JF, Bekesi JG. *Cancer Res*. 1998; 58:5389. [PubMed: 9850070] (b) Zhang C, Yang N, Yang C, Ding H, Luo C, Zhang Y, Wu M, Zhang X, Shen X, Jiang H. *PloS one*. 2009; 4:e4881. [PubMed: 19293927] (c) Rai A, Surolia A, Panda D. *PloS one*. 2012; 7:e44311. [PubMed: 22952952] (d) Rashid A, Kuppa A, Kunwar A, Panda D. *Biochemistry*. 2015; 54:2149. [PubMed: 25747795]
26. cLogP 5.23 versus 5.61 for **1** and **7**, polar surface area unchanged (ChemBio3D Ultra).

27. The target molecule (analog) is intrinsically more complex than the natural product (added complexity), and the change is benign in the sense that it does not alter the existing functionality, perturb the conformational properties, or add new functional groups to the natural product. Herein, this arises through an alteration in the core structure of the natural product.
28. Taken from reference 18a and in the words of Leonardo da Vinci: "Where nature finishes producing its own species, man begins, using natural things and in harmony with this very nature, to create an infinity of species."

Figure 1.
 Natural products.

Figure 2.

Top: X-ray crystal structure of tubulin-bound vinblastine (pdb 1Z2B)⁵ highlighting the C20' ethyl binding site at the dimer-dimer interface where vinblastine binds (left) and site of binding with top of proteins removed to visualize bound vinblastine (right). Bottom: Original protocol for accessing vinblastine and modified coupling and subsequent HAT oxidation for accessing **7**.

Figure 3.
Coupling of **6** with vindoline and cell growth inhibition of **7**.

Figure 4.

Tubulin (0.1 mg/mL, 0.91 μ M) was incubated with BODIPY-vinblastine (BODIPY-VBL, 1.8 μ M) and either vinblastine or compound **7** (18 μ M) at 37 °C in PEM buffer containing 850 μ M GTP. The BODIPY-VBL fluorescence intensity (FI) (ex: 480 nm, em: 514 nm) of 100 μ L aliquots from each incubation were measured in a fluorescence micro-plate reader at 37 °C. Control experiments were performed with BODIPY-VBL (control 1) in the absence of a competitive ligand (maximum FI enhancement due to tubulin binding) and (control 2) in the absence of tubulin (no FI enhancement due to tubulin binding). % BODIPY-VBL displacement was calculated by the formula (control 2 FI – experiment FI)/(control 2 FI – control 1 FI) $\times$ 100. Reported values are the average 4 measurements $\pm$ the standard deviation.

Scheme 1.